<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi> (<z:chebi fb="0" ids="50659">Multaq</z:chebi>), an analogue of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (Cordarone), was designed to cause fewer adverse effects than the parent compound </plain></SENT>
<SENT sid="1" pm="."><plain>Studies have indeed shown <z:chebi fb="0" ids="50659">dronedarone</z:chebi> to be safer than <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, but less effective </plain></SENT>
<SENT sid="2" pm="."><plain>Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> or <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> and other <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, reflecting the parameters of its effectiveness in clinical trials </plain></SENT>
</text></document>